Sorry T but I think you might have meant to say they do everything to help themselves
Always have, but it's become more prominent over the past few months just how much distain is displayed to shareholders.
Actually, I have to correct myself a bit on that, because they're also showing distain towards the Medical Community as regards research on Multiple Sclerosis. They like to throw a carrot out there knowing their donkey will never benefit from it.....
The following is a piece from stock head in Mid-2020
From gold explorer to hemp sellerCann Global has a long history on the ASX dating back to 2008, but is unusual in that it’s remained in the hands of the Feldman family — Sholom Feldman is the managing director and his mother Pnina is the executive chair, a position she has held since the earliest days of the company’s ASX legacy.The company listed as a gold explorer, switched into bauxite in 2010, and changed its modus operandi again in 2017 to marijuana and hemp.Cann Global’s shares were halted in July 2018 when the ASX required it to re-comply with listed rules after the change of activity. It issued 14 supplementary prospectuses and was finally reinstated more than a year later in August 2019. The company made $428,000 in cash receipts in the March quarter from selling hemp food products and cosmetics, and spent a whopping$623,000 on administrative and corporate costs, more than double what it spent on staff and production. (Not double but this wasn't retracted either)
Poor effort for MS sufferers eh...
CGB Price at posting:
0.3¢ Sentiment: Hold Disclosure: Held
